Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,498,288
  • Shares Outstanding, K 238,159
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 192 M
  • EBITDA $ 200 M
  • 60-Month Beta 0.82
  • Price/Sales 4.85
  • Price/Cash Flow 14.83
  • Price/Book 4.83

Options Overview Details

View History
  • Implied Volatility 105.52% (+1.97%)
  • Historical Volatility 99.01%
  • IV Percentile 96%
  • IV Rank 61.08%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 2) 0.68 (6.48%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 3,736
  • Volume Avg (30-Day) 9,332
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 172,444
  • Open Int (30-Day) 111,899
  • Expected Range 9.81 to 11.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.14
  • Growth Rate Est. (year over year) +713,471.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.21 +45.49%
on 03/26/26
16.39 -35.98%
on 03/17/26
-4.66 (-30.76%)
since 03/13/26
3-Month
7.21 +45.49%
on 03/26/26
18.33 -42.77%
on 01/15/26
-7.79 (-42.61%)
since 01/14/26
52-Week
7.21 +45.49%
on 03/26/26
25.67 -59.14%
on 04/28/25
-10.42 (-49.83%)
since 04/14/25

Most Recent Stories

More News
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

SAN FRANCISCO , April 14, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's...

ADMA : 10.49 (+1.06%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised...

ADMA : 10.49 (+1.06%)
ADMA Fraud Notice: ADMA Biologics Investors are Notified the Company is being Investigated for Securities Fraud after 29% Stock Drop — BFA Law

BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.

ADMA : 10.49 (+1.06%)
Investigation Opened on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA Biologics, Inc.") concerning...

ADMA : 10.49 (+1.06%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised...

ADMA : 10.49 (+1.06%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised...

ADMA : 10.49 (+1.06%)
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or...

ADMA : 10.49 (+1.06%)
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop

BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.

ADMA : 10.49 (+1.06%)
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

SAN FRANCISCO , March 30, 2026 /PRNewswire/ -- Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's...

ADMA : 10.49 (+1.06%)
Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ: ADMA) concerning...

ADMA : 10.49 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 11.17
2nd Resistance Point 10.97
1st Resistance Point 10.73
Last Price 10.49
1st Support Level 10.28
2nd Support Level 10.08
3rd Support Level 9.84

See More

52-Week High 25.67
Fibonacci 61.8% 18.62
Fibonacci 50% 16.44
Fibonacci 38.2% 14.26
Last Price 10.49
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.